Cartesian Therapeutics, Inc. Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings
Cartesian Therapeutics, Inc. (RNAC) reported Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings of -$6.89 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-13.
Financial Statements › Income Statement › Other Income
us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings · last filed 2025-03-13
- Cartesian Therapeutics, Inc. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, gain (loss) included in earnings for the quarter ending 2024-12-31 was $0.00.
- Cartesian Therapeutics, Inc. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, gain (loss) included in earnings for the quarter ending 2024-09-30 was $0.00.
- Cartesian Therapeutics, Inc. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, gain (loss) included in earnings for the quarter ending 2024-06-30 was $0.00.
- Cartesian Therapeutics, Inc. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, gain (loss) included in earnings for the quarter ending 2024-03-31 was -$6.89M.
- Cartesian Therapeutics, Inc. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, gain (loss) included in earnings for fiscal 2024 was -$6.89M.
- Cartesian Therapeutics, Inc. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, gain (loss) included in earnings for fiscal 2023 was -$149.60M.
| Period end | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings 3 month | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings 6 month | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings 9 month | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $0.00 derived: sum of 2 quarters · filed 2025-03-13 | $0.00 derived: sum of 3 quarters · filed 2025-03-13 | -$6.89M 10-K · filed 2025-03-13 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | -$6.89M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$6.89M 10-Q · filed 2024-08-08 | ||
| 2024-03-31 | -$6.89M 10-Q · filed 2024-05-08 | |||
| 2023-12-31 | -$149.60M 10-K · filed 2024-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |